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Novel research in antimicrobials is desperately needed due to high levels of 
antimicrobial resistance. It has been predicted that by 2050 antimicrobial resistant 
bacteria will be the cause of more deaths globally per year than cancer.2 Herein, is the 
study of novel supramolecular self-associating amphiphilic compounds and their 
selectivity towards bacterial membranes. Here model membranes are formed 
mimicking bacterial cells and mammalian cells for comparison. The model membranes 
are termed nanodiscs and consist of lipid bilayers solubilised with a co-polymer.  
Nanodiscs provide an excellent mimetic system for the investigation in binding 
association studies through nuclear magnetic resonance (NMR). This investigation 
determines how different constituents attached to the same molecules affect their 
hydrogen bond donating (HBD) and hydrogen bond accepting (HBA) functionalities, 
through NMR analysis. The HBD/HBA causes membrane disruption and therefore 












 Background  1.1.
Novel research to discover new antibiotics has become increasingly important in recent 
years due to antimicrobial resistance rising to dangerously high levels. Increasingly, 
governments around the world are now seeing the lack of new antibiotics as a major 
health issue, which is so serious that it threatens modern medicine. A post-antibiotic 
era, in which common infections and minor injuries can become deadly is a very real 
possibility for the 21st century.1 In 2014 the UK conducted a government review (See 
Figure 1) and predicted that by 2050 the amount of global deaths caused by 
antimicrobial resistant bacteria, could rise to 10 million, this will far exceed those 
attributed to cancer. 1 
 




Sir Alexander Fleming, in 1945, discovered penicillin and shared his vision as a 
cautionary tale when awarded his Nobel Prize. 3 He  warned against its misuse stating  
“it is not difficult to make microbes resistant to penicillin in the laboratory by exposing 
them to concentrations not sufficient to kill them.” 4 In his account Fleming was referring 




 Bacteria cell walls 1.2.
Bacteria are prokaryotic living organism that can spread quickly and reproduce, to 
ensure its survival. They can be classified as two major groups, as developed by 
Christian Gram (1884) gram-positive and gram-negative bacteria.5 This classification is 
derived from gram staining, whereby the bacterium maintains the colour of a crystal 
violet stain then it’s gram-positive. Whether or not the bacteria can retain the stain is 
based on the differences between the chemical and physical properties of their cell 
walls. Gram-positive bacteria have a thicker relatively impermeable wall, composed of 
peptidoglycan, which retains the crystal violet on the surface of the cells. Gram-
negative has a thinner peptidoglycan wall, with an overlying lipid-protein bilayer outer 
membrane, this doesn’t retain the violet stain will decolorize and stain red. This 
distinguishes between gram-positive and gram-negative groups by colouring these 
cells red or violet.6  
The cell walls are known as the cell envelope. The cell envelope is a complex 
multilayer structure that allows selective passage of nutrients from the outside, and 
waste products from the inside, it helps them to survive and protects the bacteria from 
the environment that surrounds them.7 Bacterial cell walls are much more complex than 
just the lipid membrane; a large portion of the gram-positive wall is comprised a thick 
layer of peptidoglycan with embedded teichoic acid. Gram-negative bacteria cell walls 
are structurally more complex, they contain a thin layer of peptidoglycan inner 
membrane, and an outer cytoplasmic membrane containing lipopolysaccharide 8 
(Figure 2). This is an essential toxin that protects the cell from the hosts immune 






Figure 2: Gram-negative bacteria and gram-positive bacteria.  
 
Bacteria can develop defence systems to resist the effects of the antimicrobials, for 
example they can undergo modifications where they produce enzymes that can 
inactivate the antimicrobial such as β-lactamase. This enzyme inactivates 
some penicillin, rendering them harmless to bacteria.  Another common defence 
system is the acquirement of additional efflux pumps that can remove the toxins of the 
antimicrobials from within the cell, more rapidly than it can enter. These multidrug 
resistance efflux pumps have been observed with Staphylococcus aureus and among 
other bacterium. 10 
 
 Phospholipids in the cytoplasmic membrane 1.3.
Biological membranes form cells that are continuous structures, separating the 
aqueous phases between the inside and outside of the organism. They also enable 
living organisms to produce energy and are relatively impermeable, which enables 
them to be selective towards the substances that enter and leave the cell. They can 
regulate the communication between cells by sending, receiving and processing 
information in the form of chemical and electrical signals.11  
13 
 
The three major classes of membrane lipids in the cell membrane are phospholipids, 
glycolipids, and cholesterol. Eukaryotic membranes contain  large amounts of 
cholesterol.12 Phospholipids are the most dominant lipid in the cell membrane; they are 
amphiphilic molecules with hydrophobic tails (”water-fearing”) and hydrophilic head 
groups (”water-loving”) which tends to associate with water. These head groups can be 
charged or neutral. When in an aqueous environment the amphiphilic characteristic of 
the phospholipids, drives the assembly of these lipids into bilayers, where the 
hydrophobic tail of the lipids in each layer is directed inward, and the hydrophilic head 
groups are exposed to the aqueous environment, these bilayers form the cells wall 
barrier.13 14 
The structure of phospholipid head group, determines how they are classified. An 
example of this head group classification is glycerophospholipids, their general 
structure consists of a glycerol phosphate backbone that is ester-linked to two fatty acyl 
chains at the sn-1 and sn-2 positions and a polar head group at the sn-3 position, via a 
phosphodiester bond.15 There is an exception to this rule, with mitochondrial lipid 
cardiolipin (CL), as it contains 4 acyl chains.16  
The most abundant phospholipid in eukaryotic  cells is PC, which makes up 40 to 50% 
of the total cellular phospholipids, the next most abundant phospholipid in is PE, which 
make up ~ 40% of total phospholipids.17 The PE phospholipids are located on the inner 
leaflet of the membrane.18  PC and PE are both structurally related, as they both have 
a phosphate group in their headgroup, (Figure 3). These are classified as zwitterionic 







Figure 3: PE and PC phospholipid head groups 
 
In bacteria the most abundant zwitterionic phospholipid present is PE. In general 
Gram-negative bacteria have a higher content of PE than Gram-positive bacteria. All 
bacteria also have at least 15% of anionic lipids, which is independent to whether they 
are gram-positive or gram-negative. The most abundant anionic lipids in bacteria are 
phosphatidylglycerol (PG) and cardiolipin (CL). These anionic lipids are targeted by 
cationic antimicrobial agents, which are selective towards bacteria cells,  but not 
against mammalian cells.21 19  
Although structurally related the PC head group is larger than the PE headgroup, due 
to the three methyl groups attached to the amine in PC. This causes sterically hindered 
electrostatic interactions, which interferes with the PC headgroup forming hydrogen 
bonds. This affects the hydration level of PC which is higher than that of PE and 
causes  weaker lipid to lipid interactions in PC.19  
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 Lipid Structures  1.4.
Due to the amphiphilic nature of lipids they assemble in to different structures when 
dispersed in an aqueous environment. The self-assembly occurs due to the hydrophilic 
head groups, which have a preference to interact with water and the hydrophobic tails 
repel water forming a bilayer. Different shaped structures can form which is dependent 
on the shape and the concentration of lipids in solution.22  
Lipids have polymorphic capabilities; they are able to exist as different shapes. Their 
ability to adopt different structures is due to their geometry.23,24 For example micelles, 
(Figure 4)   are formed  where the headgroup  of the lipid is larger than the hydrophobic 
tail, giving an overall inverted conical shape.19 Many molecules such as detergents will 
form spherical structures, with the head groups surrounded by water and the 
hydrophobic tails sequestered in the interior. 22  
The inverse micelle has the opposite formation, and occurs when the tails are bulky 
and the headgroup is relatively small, giving an overall conical shape19(Figure 4), this 
leads to aggregated structures with a negative curvature, such as the inverted 
hexagonal phase (HII).  
Another common structure is the lipid bilayer, where the lipids contain a large head 
group with two hydrophobic tails, such as PC and PE lipids.19 In aqueous solutions they 
adopt a bilayer structure,(Figure 4) by arranging in a parallel orientation, with the 









           
 




Figure 4: Molecular shapes of lipids. 
 
The lipid structures can assemble in different forms, by changing the conditions of the 
solution, such as the electrolyte concentration, the pH, or temperature. For lipid 
structures to assemble the lipids must first pass from the ordered gel phase, the phase 
transition temperature needed to induce this change in the lipids physical state, for 
each one is different. In the gel phase the hydrocarbon chains are fully extended and 
closely packed, and in the liquid-crystal phase, the hydrocarbon chains are randomly 
oriented and fluid.25 This provides the lipids enough mobility to align correctly and form 
structures such as micelle or a lipid bilayer. 19,22   
The phase transition temperature can be affected by many factors including the 
hydrocarbon chain length and headgroup species, charge and decrease in the order of 
desaturated to mono-unsaturated to di-unsaturated lipids.22 Generally transition 
temperature values increase with the increasing acyl chain. This is due to an increase 
in van der Waals interactions, which in turn requires more energy to disrupt the ordered 
packing.  On the other hand, introducing a cis double bond into the acyl chain produces 
a bend in the chain, which requires much lower temperatures to induce an ordered 









species can be seen with PE and PC lipids. These both have similar acyl chain lengths, 
but with the smaller PE headgroup the acyl chains are more tightly packed. This gives 
rise to the transition temperature of PE to be around 20 °C higher than that of PC. 22,19 
 
 Antimicrobials  1.5.
The term “antimicrobial” is used to describe substances that have the ability to reduce 
the presence of micro-organisms such as bacteria, fungi, helminths, protozoa and 
viruses. They can be disinfectants, anti-viral, antifungal, antiseptics, and antibiotics.26 
Antibiotics can be derived from living organisms or can be made synthetically. They 
have the ability to be bactericidal agents that kill the microbes or bacteriostatic agents, 
which slow down or stall bacterial growth.26  
Antimicrobials have different modes of action which can either inhibit cell growth or 
initiate cell death. Unlike eukaryotic cells bacteria have structural cell wall containing 
peptidoglycan. Penicillin inhibits the bacteria from forming an intact peptidoglycan cell 
wall.26 This results in a very delicate cell wall that does not support the growth of the 
cell causing it to burst, killing the bacteria.  
Some antimicrobials also selectively eradicate bacteria by affecting their metabolic 
pathways, inhibiting cellular function. The folate metabolic pathway leads to synthesis 
of required precursors for cellular function and are both present in prokaryotes and 
eukaryotes. This pathway has dihydrofolate reductase (DHFR) which is a critical 
enzyme, where micro-organisms folates must be synthesised this is vital for the cells to 
metabolise amino acids and are required for cell division. 27 Another anti-folate target is 
dihyropteroate synthase (DHPS), which is an enzyme absent in eukaryotes. The 
enzyme DHFR is targeted by trimethoprim for antibacterial uses, which contains 
Sulphonamides, such as sulfamethoxazole, this prevents the bacteria from using para-
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aminobenzoic acid for folate biosynthesis.28 Once the enzyme  is inhibited  the bacteria 
can no longer grow.27  
Another mechanism of action is the inhibition of protein synthesis leading to impaired 
growth.  An example of this is the antibiotic is tetracycline that inhibits bacterial growth 
by stopping protein synthesis. Both prokaryotic and eukaryotic cells carry out protein 
synthesis on ribosome structures. But prokaryotic cells have an active uptake 
mechanism that is not found in eukaryotic cells, and this is exploited.  Tetracycline can 
bind in high concentrations to a single site on the 30S ribosomal subunit of bacterial 
ribosomes, this inhibits the binding of aminoacyl-tRNAs stopping protein synthesis. 26,  
Fluoroquinolones such as ciprofloxacin can specifically target and block the ligase 
domain of DNA gyrase (topoisomerase II) in bacteria. These enzymes can relax tightly 
wound chromosomal DNA, which are essential for the replication and repair of the 
DNA. With the inhibition of this enzyme the bacteria is killed, and the human host isn’t 
affected. Ciprofloxacin is bactericidal towards some gram-positive and most gram-
negative bacteria.26  
 
  Antimicrobial Resistance 1.6.
While antibiotic use is rising, the pace at which we are discovering novel antibiotics has 
slowed drastically.2 Research in new antibiotics has diminished over the past decades 
due to the lack of return on the pharmaceutical companies’ investment.29 This is due to 
their short term use and they often become unusable due to the microbes becoming 
resistant to the new drugs. The amount of approved antimicrobials has also declined, 
due to unacceptable side effects and difficulty demonstrating they are not inferior to 
existing drugs already available.30 
Antimicrobial resistance is now one of the biggest threats to global health, food 
security, and development. Microbes can develop a resistance mechanism in various 
19 
 
ways, one mechanism is through selective pressure, this occurs naturally when the 
bacteria grows, it can develop mutations in its DNA that result in resistance to certain 
types of drugs. Microbes  present without the resistance mechanism will be inhibited or 
will die, and the ones that carry resistant genes can survive and multiply  by dividing 
over time, which can be hours or just a few minutes, giving a resistant  strain.31   
The misuse of antibiotics through societal pressures has unintentionally helped drive 
this evolution forward with the widespread use, which are sometimes unnecessary.  An 
example of this is when a healthcare provider has prescribed an antibiotic, due to a 
demanding patient, prior to a diagnosis. Also broad-spectrum antibiotics are prescribed 
to patients instead of a specific antibiotic due to incomplete information to diagnose an 
infection. The increased use of antibiotics in hospitals on critically ill patients can create 
an environment where antimicrobial resistant microbes can spread easily. A growing 
number of infections, such as pneumonia and tuberculosis are becoming harder to 
treat as the antibiotics used to treat them become less effective. Antibiotics are also 
misused agriculturally, where antibiotics are added to agricultural feed, as a precaution 
to maintain healthy animals, this promotes drug resistance, which can escalate the 
speed at which bacteria can evolve into superbugs.31  
The organisms posing the most danger are known as “ESKAPE pathogens” which 
include, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species, these 
are both Gram-positive and Gram-negative species and have the ability to evade the 







 Global action plan on antimicrobial resistance  1.7.
In 2015 The World Health Organization created a five objective global action plan to 
address antimicrobial resistance, which outlines five objectives: 33 The objectives focus 
on developing new antimicrobial drugs and slowing down microbe evolution by 
decreasing the misuse and overuse of the antimicrobial drugs. 
 
The five objectives   
1. Improve awareness and understanding of antimicrobial resistance through effective 
communication education and training. 
2. Strengthen the knowledge and evidence base through surveillance and research 
3. Reduce the incidence of infection through effective sanitation, hygiene and infection 
prevention measures. 
4. Optimize the use of antimicrobial medicines in human and animal health. 
5. Develop the economic case for sustainable investment that takes account of the 
needs of all countries and to increase investment in new medicines, diagnostic tools, 
vaccines and other interventions antimicrobial resistance and to coordinate numerous 
international sectors. 
 
 Membrane mimetics  1.8.
The natural membrane is a complex environment and this has led to an interest and 
need for model membranes for the study and development of the membrane.34 The 
physicochemical properties of the model lipid membranes can be controlled, leading to 
different forms of lipid structures.35 Currently the most utilised models for  cell 
membranes are liposomes, detergent stabilized micelles, bicelle aggregates and disc 
shaped supported lipid bilayers.36  
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Liposomes are small artificial spherical vesicles, consisting of one or more lipid 
bilayers. These can be used for the study of cell interactions and drug delivery. 
Liposomes have different classifications based on size and number of bilayers. 
Unilamellar liposomes are made up of a single phospholipid bilayer sphere. These can 
be further classified into two categories: large unilamellar vesicles (LUV) and small 
unilamellar vesicles (SUV). The multilamellar liposomes have two or more bilayer 
membranes, and have an onion type structure. With many unilamellar vesicles of 
varying sizes within one another, this leads to the multilamellar structure.37 These are 
restricted by use of NMR; however micelles and nanodiscs are not. 
Nanodiscs are self-assembled soluble particles that range from ~10 to 50 nm in 
diameter. 38 They are a useful membrane mimetic system, which consists of a non-
covalent bilayer assembly of phospholipids, wrapped by either a membrane scaffold 
protein (MSP)39 or a copolymer in a belt-like configuration. The MSP is only useful 
when studying proteins; the polymer however self-inserts into membranes and extracts 
membrane patches in the form of a nanodisc 40 (Figure 5). An advantage of polymer 
belted nanodiscs is their modularity where different compositions of phospholipids can 
be incorporated, and these soluble discs can then be studied.38 Nanodiscs are often 
used in NMR spectroscopy in ligand-binding research. This is an important technique 
used within the drug discovery process for the analysis of synthetic compounds and for 
its ability to identify small ligands that bind to a specific target, such as nanodiscs. 
Information about the exact ligand binding mode is needed to improve the design of the 
ligand for its intended purpose.41 
In 2007 Sligar et al 42 developed the new technology termed nanodiscs. Since then the 
first report of a nanodisc library was recognised from E.coli membrane proteins in 2013 
by Marty et al, Where membrane proteins were extracted and incorporated into 
nanodiscs with different loading ratios,43 thus optimising the MSP to lipid ratios, and 
they quantified how efficient the integration was by SDS-PAGE gels.42  
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 Advances in lipid Solubilisation Techniques 1.9.
Due to difficulties associated with structural and functional studies of the complex 
structure of the lipid bilayer, various solubilisation techniques have been developed. 
These techniques consist of a solubilising agent that satisfies the hydrophobic nature of 
the transmembrane segments.  
The first and most common method used for membrane protein solubilisation is the use 
of detergents; these have been successful in extracting the proteins from their native 
lipid environment, and they replace the lipids with detergent molecules. Compatible 
detergents have been developed for specific membrane proteins, including non-ionic, 
sulfonated and  zwitterionic.44 Detergents as solubilising agents have their limitations; 
they tend to be denaturing which can lead to a loss in activity. This denaturing effect is 
partially improved with amphipols, which are a  class of surfactants, containing 
amphiphilic polymers,45 designed to keep membrane proteins soluble in water without 
the need for detergents, but they still denature sensitive proteins. With the side effects 
of the amphipols and detergents, other alternative strategies for solubilisation have 
been developed to better mimic the cellular membrane.46 
In the past few years, the styrene maleic acid (SMA) copolymer has gained attention as 
a detergent-free approach for membrane solubilisation. 47 The amphipathic polymer 
solubilizes intact membrane patches in the form of nanodiscs; these particles are 
referred to as styrene maleic acid lipid particles (SMALPs). 46 The solubilisation of the 
bilayer membrane occurs in three stages. Initially the SMA will bind to the surface of 
the membrane. Next the polymer molecules insert into the hydrophobic core of the 
membrane, driven by the hydrophobic effect. Finally, the membrane is solubilized and 
nanodiscs are formed.47 (Figure 5) The planar lipid bilayers discs formed are suitable 





Figure 5: Nanodisc formation 
The SMA polymer has many advantages it extracts the lipids in a water-soluble form, 
reducing disruption to the patch of membrane around them, thus keeping them stable 
as a SMALP complex. 47  
SMALPs can be constructed in different sizes which depend on the molar ratio of 
styrene to maleic acid, the general size of the 2:1 ratio SMALP is around ~10 nm.49 
SMA also has its drawbacks as it is pH sensitive, in acidic conditions below a pH of 6.5, 
50  it will precipitate  and in the presence of  divalent cations, which are  required for 
many applications.51  More recently poly (styrene-co-maleimide) (SMI), a modification 
of SMA has been successful in overcoming these limitations.  SMI forms similar 
nanodiscs in the size range 6 to 12 nm, with comparable efficiency to SMA, and isn’t 
affected by acidic pH or high concentrations of divalent cations.51 
 
  Synthetic Amphiphiles  1.10.
Amphiphilic is a term used to describe a chemical compound that possesses both 
hydrophilic and hydrophobic region linked by covalent bonds. The hydrophobic regions 
facilitate insertion of  molecules into the hydrophobic regions of bacterial lipid 
membranes, which induces membrane disruption.52  
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Detergents are amphiphilic molecules, and can insert their hydrophobic tails into the 
lipid membrane, causing disruption as the concentration of detergent increases.50 
These molecules transform into detergent–lipid–protein mixed micelles which extract 
the membrane-embedded proteins.53 this is one of the most widely used agents for 
membrane protein extraction and stabilisation in experimental studies.  
Research with synthetic amphiphilic compounds, has shown that they can self-
associate in to larger structures, where they form well-defined structures in aqueous 
solutions. The self-assembly of these molecules is the same as phospholipids with the 
formation of non-covalent bond interactions,  these  include, but not limited to  
electrostatics, π−π stacking, charge transfer, and hydrogen bond formations.14  The 
construction of various monomeric units, was explored with different constituents, and 
revealed that these interactions dictated the global solution and solid state properties of 
the formed structures.54,55 
Research into amphiphilic compounds as medicines, has been of increasing interest in 
the recent search for novel antimicrobials.  A recent study of  supra molecular self-
associating amphiphilic compounds was investigated and demonstrated how the 
molecules self-assemble at the molecular level, this  permitted the design and 
formation of over 65 self-associating compounds, which contain hydrogen bond 
donating (HBD) and accepting (HBA) functionalities in the structure.  
The self-associative and physicochemical properties for  over 30 of these self-
associating amphiphilic compounds was investigated for structure–activity relationships 
in the solid, solution and gas phases as well as  antibacterial activity. Here they found 
that the formation of self-associated structures is imperative for delivery of the 
compound to the bacterial cell, resulting in membrane disruption. 56 These compounds 
have a general structure with a hydrogen bond donor group and an acceptor group that 
can self-associate through one or more hydrogen bonds and usually the integration of 
an aromatic moiety. The hydrogen bond donor group is usually urea or thiourea, and 
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the hydrogen bond acceptor group is usually a sulfonate or phosphate moiety, however 
there are many other constituents that have been investigated, with the number of 
possible structures continuously growing.56,54  These structure—activity studies from 
the general structure has shown to increase the antibacterial efficacy and  have shown 
antibacterial activity towards methicillin-resistant Staphylococcus aureus, which is one 
of the  “ESKAPE” pathogens.56  
 
 Research on Antimicrobial activity with mimetic membranes  1.11.
A recent study investigated the associations between designer antimicrobial peptides 
with the phospholipid bilayer. The insertion of the cationic peptides in to the membrane 
altered the organisation and fluidity of the membrane. This created fluid areas in the 
packing of the phospholipids, which led to the delocalization of membrane bound 
proteins, contributing to the cells destruction. This study was conducted on model 
membrane system of Bacillus subtilis, with variations in the phospholipid composition. 
This better explained the implications of using model membranes in experimental 
studies, as these have defined properties, unlike biological membranes, which is often 
disputed. The results indicated that  changing the lipid compositions of the bacterial 
membrane didn’t affect susceptibility to the peptides.57  
In another study by U. Divakara et al 58 in 2016, it was reported that maleic anhydride 
based novel cationic polymers, joined with amide side chains showed antibacterial 
efficacy against many “ESKAPE” pathogens. These polymers interact with the bacterial 
cell membranes by causing membrane depolarization, permeabilization and energy 
depletion. This was achieved by modifying the side amide chains which optimised the 
hydrophobicity of the amphiphilic polymers; this played an important role in selective 




 Project Aims and Objectives  1.12.
The aim of this project is to study synthetic compound-membrane interactions, aiding 
research in the fight against antimicrobial resistance.  
The synthetic compounds used in this study, are novel Supramolecular Self-
associating Antimicrobials SSAs, these form part of a novel family of amphiphilic 
molecules. The three compounds selected each have unique substituents attached to 
the general structure shown in Figure 6. With R= Chemical substituents, A= anionic 
group, Y= cationic group, X= Oxygen/Sulfonate. It has been hypothesised that these 
create antimicrobial selectivity towards the phospholipid bilayers. 





Figure 6:  General molecular structure of first generation amphiphilic molecules.  
It has been confirmed in previous studies that the SSA monomers will self-associate 
through hydrogen bonding. This is significant to the antimicrobial activity of these 
molecules.  Models for the complex include but not limited to; dimer formation through 
the creation of four urea-anion hydrogen bonds and polymerization55,54 as illustrated in 
Figure 7. The complexes formed increase in size, with the increase in concentration of 
the SSA. In this study experiments were not preformed to confirm how the 
concentration affects the structure; however this has been confirmed with previous 
studies conducted by L.White et al. 61 The accuracy of these predicted models form 







Figure 7:  SSA schematic illustrating self-association  hydrogen bonding motif. 
My aim was to determine which compounds display a stronger binding affinity towards 
different types of phospholipid membranes, comparing those of bacterial and 
eukaryotic cells. The phospholipid bilayers were belted together with an appropriate 
synthetic polymer, which formed disc shaped planar bilayers (nanodiscs). These 
nanodiscs required a lipid composition comparable to bacterium cells and a second 
type of nanodisc comparable to mammalian cells. The resulting nanodiscs were 
characterised, purified and quantified to enable accurate results. The SSAs were 
hypothesised to interact with lipids primarily through the formation of hydrogen bonds 
and electrostatic interactions; these were investigated with NMR 1H analysis.  
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 Chemical Structures    1.13.
 
The SSAs used within this study include:  
 MW 539.478 g/mol 
MW 618.896 g/mol 
MW 604.87 g/mol 
 
Figure 7: Chemical structures, compounds 1-3 + Tetrabutylammonium 
 
These structures have been chosen, as they all contain the same HBA/HBD 







2. Materials and Methods 
 General 2.1.
Compounds 1-3 were obtained from L. White, a PHD student within the J.Hiscock 
Laboratory. Compound 1 MW 539.478 g/mol, compound 2 MW 618.896 g/mol and 
compound 3 MW 604.87 g/mol. SMI2000I resin, MW of 7500 and SMA2000 (poly(styrene-
co-maleic anhydride) SMAnh), MW of 7500, sourced from Cray Valley. E.coli Total 
lipids purchased from Avanti Polar stored at -80 oC. 14:0 PC (DMPC) 1,2-dimyristoyl-
sn-glycero-3-phosphocholine, MW 677.933 purchased from Avanti Polar Lipids, stored 
at -20 oC. Phosphate buffer NaCl 20 mM Na2PO4, 20 mM pH 7.0 and Phosphate buffer 
NaCl 20 mM Na2PO4  20 mM pH 7.4, was filtered and degassed prior to use. All 
solvents and starting materials were purchased from commercial sources or chemical 
stores where available and used as purchased unless stated otherwise. 
 
  Solubilisation of Poly(styrene-co-maleimide) (SMI) 2.2.
SMI2000I polymer was hydrolysed under reflux conditions. SMI resin (25 g) was initially 
ground in a pestle until a fine powder was obtained. The resulting powder suspended in 
HCl (250 mL, 1 M) with anti- bumping granules (0.1 g) and slowly heated to reflux (100 
°C) with constant stirring. Solution refluxed for ~4 hours, until all of the solid SMI 
dissolved, giving a pale yellow colour. Once the solution cooled (20 oC) The SMI was 
precipitated by increasing pH to 8 with the addition of NaOH (5 M), and checked using 
pH paper. The precipitated polymer was centrifuged at 11,000 g for 15 minutes (4 oC), 
the supernatant was removed and the precipitate was washed 3 times with Milli Q 
water (250 mL). The polymer was suspended in HCl (0.6 M) and adjusted to pH 7.4, 
and left in an incubator overnight to dissolve, once completely solubilised the polymer 





 Solubilisation of Styrene-maleic Anhydride (SMAnh)   2.3.
SMA2000 polymer was hydrolysed under reflux conditions. SMA anhydride powder (25 
g) was suspended in NaOH (250 mL, 1 M) with anti- bumping granules (0.1 g) and 
slowly heated to reflux (100 °C) with constant stirring. Solution refluxed for ~4 hours, 
until all of the solid SMA dissolved. Once the solution cooled (20 oC) The SMA was 
precipitated by reducing the pH to below 5 with the addition of concentrated HCl. and 
checked using pH paper. The precipitated polymer was centrifuged at 11,000 g for 15 
minutes (4 oC), the supernatant was removed and the precipitate was washed 3 times 
with Milli Q water (250 mL). The polymer was suspended in NaOH (0.6 M) and 
adjusted to pH 7.4, and left in incubator overnight to dissolve, once completely 
solubilised the polymer was lyophilized and stored at room temperature.  
 
  SMILPs preparation 2.4.
E.coli Total lipid extract (10 mg) was dissolved in methanol and chloroform (1:1 ratio) 
and evaporated under a stream of Nitrogen gas, to a thin lipid film. The resulting lipid 
film was dried for a further 1 hour under nitrogen gas. Next the lipid film was hydrated 
with phosphate buffer (pH 7) (1 mL) sonicated and vortexed vigorously.  SMI (50 mg) 
was added to the opaque lipid solution and incubated for 1 h at 37 °C, giving a 
translucent solution.  
 
 SMALPs preparation 2.5.
E.coli Total lipid extract (10 mg) was dissolved in methanol and chloroform (1:1 ratio) 
and evaporated under a stream of Nitrogen gas, to a thin lipid film. The resulting lipid 
film was dried for a further 1 hour under nitrogen gas. Next the lipid film was hydrated 
with phosphate buffer (pH 7.4) (1 mL) sonicated and vortexed vigorously.  SMA (50 
mg) was added to the opaque lipid solution and incubated for 1 h at 37 °C, giving a 
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translucent solution. DMPC Polar Lipids (10 mg) were prepared in the same way as 
above, and incubated for 1 h at 25 °C, giving a translucent solution.   
 
 Purification  2.6.
Nanodiscs samples (1 mL) were centrifuged at 208000 g for 30 minutes at 4 oC, the 
supernatant was collected and the pellet discarded. The nanodiscs were then dialysed 
overnight against 4 L phosphate buffer ( 20 mM ) pH 7 for SMILPs and pH 7.4 for 
SMALPs with a 50 kDa cut-off dialysis tubing. 
Further purification was achieved by gel filtration chromatography where nanodisc 
samples were concentrated prior to injection, using a centrifugal concentrator with a 
30,000 Da MWCO membrane, centrifuged at 3220 g (20 min) (4oC) to below 400 µl 
and fractionated on a Superdex 200 10/300 GL column (GE Healthcare). With a flow 
rate of 0.5 ml/min, with phosphate buffer pH 7 for SMILPs and pH 7.4 for SMALPs, 
while monitoring nanodisc absorbance at 260 nm. Pump B on the machinery was 
initially washed with deionised H2O and equilibrated in the relevant buffers; all solutions 
were filtered and degassed accordingly to remove any air and small particles present. 
Fractions (0.5 ml) were collected for further analysis. 
 
 RI of Nano discs  2.7.
Nanodiscs were concentrated and purified using a centrifugal concentrator with a 
30,000 Da, MWCO membrane at 3220 g (20 min) (4oC). The refractive index was 
determined by taking the average of three samples of nanodiscs, using a manual 
benchtop refractometer ABBE 5 BS.  Hexane was used as a control with an RI 1.375. 
 
  UV-Vis Quantification 2.8.
Quantification of nanodiscs was carried out through UV-Vis spectrum using 
NanodropOne_AZY1705795. SMA (165 µM) sample was serial diluted 10 times with a 
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variety of different concentrations and each sample measured in a quartz cuvette (0.5 
mL) this was repeated 3 times. Calibration was preformed prior to use with a blank, and 
all spectra were zeroed at 750 nm. The λmax was determined and the averages of all 3 
plotted in excel giving a linear calibration curve. This was then used to quantify the 
concentration of nanodiscs in solution through the straight line equation. 
 
 DLS studies  2.9.
DLS studies were carried out using Anton Paar LitesizerTM 500 and processed using 
KalliopeTM Professional. All vials used for preparing the samples were clean and dry. 
All solvents used were filtered to remove any particulates that may interfere with the 
results obtained. The nanodisc sample sizes were kept to 0.5 mL, and allowed to 
equilibrate for 10 minutes followed by a series of 10 ‘runs’ on each sample to give 
enough data to derive an appropriate average. In some instances, the raw correlation 
data indicated that a greater amount of time may be needed for the samples to reach a 
stable state. For this reason, only the last 9 ‘runs’ were included in the average size 
distribution calculations. 
 
 Zeta Potential Studies  2.10.
Zeta potential studies were carried out using Anton Paar LitesizerTM 500 and processed 
using KalliopeTM Professional. All vials used for preparing the samples were clean and 
dry. All solvents used were filtered to remove any particulates that may interfere with 
the results obtained. The nanodisc samples were measured in an Omega cuvette 0.35 
mL, by a series of 10 ‘runs’ on each sample to give enough data to derive an 
appropriate average.  
 Transmission Electron Microscopy (TEM) Imaging 2.11.
For electron microscopy, a droplet ( 2 μL) of sample was applied to formvar/carbon 
coated 600 mesh copper grids (Agar Scientific) and left for 5 minutes at RT. Excess 
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liquid was aspirated from the grid and a drop of 2 % uranyl acetate (aqueous) was 
applied to the grid an immediately aspirated. Grids were then dried at room 
temperature. Images were recorded on a Jeol 1230 TEM operating at an accelerating 
voltage of 80 kV equipped with a Gatan One View 16 MP digital camera. 
 
 NMR 1H 1D  2.12.
NMR 1H 1D spectra were determined with a Bruker Avance III 600 Hz spectrometer at 
298 K. Data was collected with 32768 points and a spectral width of 16.0242 ppm, 
receiver gain was set to 256, with 128 scans, 4 dummy scans and an acquisition time 
of 1.7 s at 298 K. Water suppression was achieved using excitation sculpting 1D, with 
double pulse field gradient spin echo. All data was processed using Bruker topspin 
3.6.1 software, all spectra were phased, baseline corrected and calibrated to the centre 
of the DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) peak, with the chemical shifts 
reported in parts per million (ppm) the peak height in intensity [abs], (the absolute peak 
intensity) and Intensity [rel], ( the relative peak intensity). 
 
 NMR 1H CPMG 2.13.
NMR 1H CPMG spectra were determined with a Bruker Avance III 600 Hz spectrometer 
at 298 K. Data was collected with 16,384 points and a spectral width of 16.0242 ppm, 
receiver gain was set to 256, with 128 scans, 16 dummy scans and an acquisition time 
of 0.85 s at 298 K. Water suppression was achieved using pre-saturation Watergate 
block dpfgse_water. The CPMG element used  300 cycles and a delay of 1 ms 
between 180-degree pulses, Data was processed using Bruker topspin 3.6.1 software, 
all spectra were phased, baseline corrected and calibrated to the centre of the DSS 
(4,4-dimethyl-4-silapentane-1-sulfonic acid) peak, with the chemical shifts reported in 
parts per million (ppm), the peak height in intensity [abs], (the absolute peak intensity) 




 NMR Titration  2.14.
Stock solutions of compounds 1-3 5000 µM (550 µL) were dissolved in phosphate buffer 
(pH 7.4). Compound 1 (539.478 g/mol) (1.48 mg), compound 2 (618.896 g/mol) (1.70 mg) 
and compound 3 (604.87 g/mol) (1.66 mg). To ensure full solubilisation the compounds 
were sonicated, heated where necessary and vortexed vigorously.  The stock solutions of 
compounds 1-3 were further diluted to 100 µM (550 µL) before adding to an NMR tube (5 
mm). SMALPs were added step-wise to the SSA at varying concentrations starting at 0.01 
µM up to 100 µM. NMR 1H 1D and CPMG spectra were obtained at each step, no extra 
time was given for equilibration. The addition of the SMALPs to the compound gave rise to 
the concentration of compounds 1-3 decreasing during the experiment; this was corrected 
by calculating the increase in volume, (Table 1), which led to a lower concentration of the 
compound at each step and reporting the final result as a molar ratio. The intensity % of 
the peaks chosen was plotted against the molar ratio of compound: SMALP.   
 
Table 1: Molar ratio of compound 1-3 to SMALP 
 
 
SSA (µM) E.coli SMALP (µM) Molar ratio SSA (µM) DMPC SMALP (µM) Molar ratio
100.0 0.0 0.000 100.0 0.0 0.000
99.7 0.2 0.002 99.5 0.2 0.002
99.3 0.4 0.004 99.0 0.4 0.004
99.0 0.6 0.006 98.6 0.6 0.006
98.7 0.8 0.008 98.1 0.8 0.008
98.3 1.0 0.010 97.6 1.0 0.010
97.5 1.5 0.015 96.5 1.5 0.016
96.8 2.0 0.021 95.4 2.0 0.021
95.2 3.0 0.032 93.2 3.0 0.032
93.7 4.0 0.043 91.1 4.0 0.044
93.4 6.0 0.064 90.7 6.0 0.066
93.1 8.0 0.086 90.3 8.0 0.089
92.8 10.0 0.108 89.9 10.0 0.111
92.1 15.0 0.163 89.0 15.0 0.169
91.4 20.0 0.219 88.0 20.0 0.227
90.7 25.0 0.276 87.1 25.0 0.287
87.4 50.0 0.572 82.7 50.0 0.605
84.3 75.0 0.890 78.8 75.0 0.952
81.4 100.0 1.229 75.2 100.0 1.330
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3. Results and Discussion  
  General Structure of Compounds   3.1.
All compounds used in this study form part of a series of novel supramolecular 
amphiphilic antimicrobials. The general structure consists of a hydrogen bond donor 
group and an acceptor group in one molecule that can self-associate through one or 
more hydrogen bonds.  
For this study the interactions between SMALPs and three individual amphiphilic 
compounds were investigated.  
Compound 1: consists of a (trifluoromethyl)benzene aromatic, with a HBD and HBA 
urea moiety, and a HBA sulfonate functionality, with a  TBA  counter cation (Figure  7). 
Compound 2: Consists of 2-phenylbenzo[d]thiazole fluorescent moiety in the para 
position, with HBD, HBA urea moiety and HBA sulfonate functionality, with a TBA 
counter cation (Figure  7).  
Compound 3: Consists of a 2-phenylbenzo[d]thiazole fluorescent moiety in the ortho 
position, with HBD, HBA urea moiety and HBA sulfonate functionality, with a TBA 














  Poly(styrene-co-maleimide) (SMI2000I) 3.2.
SMI2000I was not soluble in a deprotonated form, the method used to solubilise the resin 
was protonation, which formed a soluble salt acid from the Poly(styrene-co-maleimide). 
This involved the use of a reflux setup, which gradually heated the solution to reflux at 
100 °C. Prior to adding the resin to the HCl the resin was ground in a pestle until a fine 
powder to reduce the reaction time. The HCl gave an acidic aqueous environment, 
which led to protonation of the ternary amine, giving a cationic derivative. The 
protonation of the ternary amine group was essential in the polymer becoming water 
soluble.59 (Figure 9) Next the polymer was precipitated by increasing  pH to 8 with the 
addition of NaOH, and washed before undergoing lyophilisation, which resulted in a dry 
white powder.  
 




 Styrene-maleic Anhydride (SMAnh) 3.3.
SMA2000 was not soluble as an anhydride, the method used to solubilise the powder 
was deprotonation, which formed a soluble acid from the SMAah. The method used for 
the hydrolysis of the anhydride to the acid involved the use of a reflux setup, which 
gradually heated the solution to reflux at 100 °C. The NaOH gave an alkaline aqueous 
environment, where the hydroxide ions were consumed. This was by either acting as a 
nucleophile and reacting with the anhydride ring and/or acting as a base deprotonating 
the resulting carboxylic acids (COOH → COO−) that were formed when the anhydride 
ring opened. The deprotonation of the acidic groups was important in the polymer 
becoming water soluble.60 (Figure  10) Next the polymer was precipitated by reducing 
the pH to below 5 with the addition of concentrated HCl. and washed before 
undergoing lyophilisation, which resulted in a dry white powder. 
 




  Nanodiscs 3.4.
There are three types on nanodiscs that were investigated, E.coli SMILPs, E.coli 
SMALPs and DMPC SMALPs. Here E.coli lipids are representing a prokaryotic 
bacterial membrane, with PE as the most abundant lipid present and the DMPC lipids 
represent a eukaryotic mammalian membrane.  
DMPC lipid nanodiscs alone are a simplistic mimetic of the eukaryotic membrane; for 
this preliminary study it’s suitable as a model due to the composition of the outer 
eukaryotic membrane containing predominantly PC lipids. Although PE lipids make up 
~40% of the eukaryotic membrane these are contained within the inner leaflet, and do 
not play a part in the membrane interactions with other compounds such as SSAs, 
hence this allows for the discrimination between the membrane types.   
The difference between the SMILPs and the SMALPs was the copolymer that belted 
the lipid bilayer together. The SMI polymer was cationic and stable under both neutral 
and acidic conditions and the SMA polymer is anionic and only stable under neutral or 
basic conditions. Both of the polymers preformed similarly and were able to solubilise 
the lipid bilayers in to nanodiscs, this was observed through the solution changing 
from a cloudy solution to a translucent solution, upon the addition of the copolymer. 
With the E.coli lipid extract the transition temperature needed to be higher than the 
DMPC lipid extract. This led to a higher incubation temperature; that was a direct 
effect of the E.coli lipids containing PE as its most abundant lipid.61,62 The head group 
of the PC is larger that of PE due to the three methyl groups attached to the amine, 
which PE lipids do not have, this causes sterically hindered electrostatic interactions 
and causes weaker lipid to lipid interactions, hence less energy is required to 






  Purification of Nanodiscs 3.5.
After the nanodiscs were formed they were purified using various techniques to ensure 
a pure sample of nanodiscs. First the nanodiscs were centrifuged, at 208000 g for 30 
mins at 4 oC, this forced any unbound lipids to the bottom of the sample and only the 
supernatant was collected with the formed nanodiscs. All three samples produced only 
a small amount of insoluble material as a pellet, which was discarded. This indicated 
that the majority of the lipids were bound by the copolymers and in solution.  
Next the nanodiscs were separated from any remaining reagents and low molecular 
weight products, such as free copolymer by dialysis against 4 L phosphate buffer     (20 
mM) pH 7 for SMILPs and pH 7.4 for SMALPs with a 50 kDa cut-off dialysis tubing. The 
conditions for the SMI copolymer were required to be slightly acidic to avoid 
precipitation.  
Further purification was achieved by gel filtration chromatography, which separated the 
nanodiscs by their size. The first eluted particles are the biggest, followed by the 
smaller ones. This is due to the smaller particles spending more time in the pores, 
within the column, where the larger ones cannot fit. The elution of the nanodiscs was 
detected using UV-Vis at 260 nm, which allowed for the identification of aggregates 
containing styrene. The fractions were collected and the size of the nanodiscs analysed 
with DLS prior being mixed together and concentrated back to ~1 mL. This procedure 
assured that in every sample only the fractions containing the correctly assembled, 
homogenous nanodiscs were collected and used for further experiments. Any other 
larger or smaller aggregates that may have still been present were discarded. Fractions 
(0.5 ml) were collected for further analysis with DLS to determine the size of the 
particles.   
DLS is commonly used to detect the particle size of a sample, in an aqueous 
environment. Fractions (0.5 ml) were eluted and collected from ~10 ml to ~20 ml 
depending on UV-Vis detection, each fraction was analysed with DLS in disposable 
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cuvettes of 500 µL to determine the size of particles present. The results of the particle 
size were as expected, particles that eluted at 16.5 ml (Figure 10 a) were  ~100 nm in 
size, and the ones that eluted at 19 ml (Figure 10 b), were ~10 nm in size. Here sample 
a, was discarded and sample b, was stored at 5 oC for further studies. 
   
 
Figure 10: Gel filtration chromatography DLS results. 
 
Average intensity particle size distribution of E.coli SMALPs, in phosphate 
buffer pH 7.4, calculated from 9 DLS runs at 298 K. Error given is the standard 






 Index of refraction for Nanodiscs  3.6.
A refractometer measures the amount of light that is refracted within a sample. The 
refractive index (RI) of the nanodiscs needed to be established to aid in DLS studies on 
particle size. First the SMILP sample was concentrated in a centrifugal concentrator to 
remove excess PB, to ensure the resulting RI was from the nanodiscs and not the PB.  
The RI was determined by taking the average of three samples of nanodiscs, resulting 
in an average RI of 1.35,(see Table 1) All samples were measured on a manual 
benchtop refractometer. The RI of Hexane is well documented at 1.375 at 20ºC; this 
was used as a control to ensure the results were reliable.  
 
Table 1: Index of refraction for nanodiscs 
Sample Index of refraction 
Hexane 1.375 
Phosphate buffer  pH 7.0 1.335 
SMI copolymer 1.341 
SMILPs sample 1 1.349 
SMILPs sample 2 1.349 





The first nanodiscs investigated were the SMILPs, for their size and stability to 




3.7.1.  DLS intensity weighted particle size distribution of SMILPs  
DLS is commonly used to detect the particle size of a sample, in an aqueous 
environment. This technique can be used on a small amount of sample typically 1 mL 
and is non-invasive. This makes it an ideal tool for extensive particle analysis. 
DLS was used to establish the average intensity particle size distribution; this was done 
to determine if the nanodiscs had successfully formed. The first sample of nanodiscs 
measured was the E.coli SMILPs; these formed the majority of particles in solution 
around 10 nm, (Figure 11). This size of nanodiscs formed with SMI was coherent with 
the reported size  in literature which is around ~6 to 12 nm.51  Another peak formed 
around 100 to 1000 nm which may be due be aggregation, or dust particles. The size is 
determined by the contribution of each particle in the distribution, to the intensity of light 
scattered by the particle.63 
 
Figure 11: Average intensity particle size distribution of E.coli SMILPs. 
 
Average intensity particle size distribution of E.coli SMILPs, in phosphate buffer 





3.7.2. DLS number weighted particle size distribution of SMILPs  
The number weighted distribution is useful in determining the number of particles of a 
certain size in solution. The same set of DLS data used in plotting, Figure 12, also 
reports the average number weighted particle size distribution.  
All of the particles in solution were within the size range of ~5 nm to 12 nm, with no 
sign of larger aggregates,(Figure 12). This is due to the number contribution from the 
larger aggregates is so small (<0.001%) that it is no longer considered relevant and not 
displayed. This further confirms that the peak on Figure 11, of 100-1000 nm is from an 













Figure 12: Average number weighted particle size distribution of E.coli SMILPs.  
 
Average number weighted particle size distribution of E.coli SMILPs, in phosphate 






3.7.3. DLS correlation function data 
The correlation function gives information about the signal-to-noise ratio as well as on 
the presence of dust particles or aggregate. The degree of similarity between the 
signals is processed; a strong correlation indicates that the data is consistent and 
therefore reproducible.  
The correlation data for the SMILPs is from the same data set as the particle size 
distributions. All of the 9 runs were all consistent and therefore the data collected 
regarding the size of the particles is credible, (Figure 13).  
 
Figure 13: Correlation function data for E.coli SMILPs. 
 
The correlation function data for E.coli SMILPs was calculated from 9 DLS runs at 
298 K 
3.7.4. TEM Imaging of SMILPs  
The next step to investigate the formation of nanodiscs is to visualise them using TEM. 
After experiencing precipitation within the sample, storage conditions were 
investigated. The SMILP sample was divided in half and stored in different 
environments overnight. One was stored at 4oC and the other at RT. The sample 
stored at 4oC became slightly cloudy, indicating that the structures were disassembling.  
Images were taken of both samples for comparison. The spherical shapes in Figure 14, 
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were from the sample stored at 4oC and not believed to be nanodiscs, as the solution 
was slightly cloudy due to precipitation. The presence of formed nanodiscs in Figure 15 
is questionable. 
Negatively stained uranyl acetate TEM image showing results from E.coli SMILPs 
(Figue 14)  sample stored at 4oC, Visual evidence of nanodiscs was questionable  








Figure 14: TEM image showing results from E.coli SMILPs.  
Negatively stained uranyl acetate TEM image showing results from E.coli SMILPs 
sample stored at RT. (Figur 15)  Visual evidence of nanodiscs was questionable.  
Scale bar =100 nm     
 
Figure 15: TEM image showing results from E.coli SMILPs. 
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3.7.5. Viability of SMILPs 
SMILPs were formed successfully, however the nanodisc samples were found to be 
unstable and precipitated upon storage (4 0C) over a short period of time (~24 hours). 
Further storage conditions were investigated, such as RT, which slightly increased the 
longevity on the nanostructures. TEM images were acquired; however the identification 
of nanostructures was questionable within the images. It was also determined that the 
SMILPs were precipitating during the purification stage causing impairment to the 
Superdex 200 10/300 GL column.  Alternative purification techniques were also 
investigated, however due to the instability of the nanodiscs, the copolymer SMI was 
substituted with SMA and SMILPs were not used any further in this study. 
 
3.7.6.  Conclusion 
In literature SMI copolymer is  deemed to be a a more versatile copolymer in forming 
nanodiscs. This is due to the SMI not being affected by acidic pH or high 
concentrations of divalent cations.  
The nanodiscs in this study were formed in a neutral environment, with no divalent 
cations present, however this polymer was investigated  due to  comparable efficiency 
to SMA. 
Although the SMI has a similar thermodynamic driving force for the formation of 
nanodiscs, it was found in a study that SMI had slightly larger negative free energy 
change upon interaction with the lipids, 51 when being compared with SMA. This  
indictes a less favorable self-assembly for SMI and may of contributed to the unstability 





  SMALP Results and Discussion 3.8.
3.8.1. UV-Vis Quantification  
Nanodiscs are often quantified by the protein encapsulated within the structure; 
however in this study the nanodiscs didn’t contain any protein and so a new method 
was formulated to quantify the amount of discs in solution.  
A calibration curve is a common method for determining the concentration of a 
substance in an unknown sample by comparing the unknown to a set of standard 
samples of known concentration. 
First SMA (165 µM) was serial diluted 10 times, and the resulting absorbance at λmax 
(260 nm) was plotted against the concentration, giving a linear calibration curve (Figure 
16). This was then used to determine the concentration of the purified SMALP 
samples, by detecting the amount of SMA present. The SMALPs were diluted 1:10 
dilution prior to obtaining the absorbance value; this was due to a high absorbance 
reading with the original sample, which fell outside of the instrument's linear range. The 
final concentration was determined using the straight line equation. 𝑦 = 𝑚𝑥 + 𝑐 
 
Figure 16: Calibration curve for SMA in PB. Error given is the standard error of the mean. 
The concentration of SMA relates directly to the concentration of nanodiscs in solution. 
In literature previous studies have shown that one SMA chain will form one nanodisc.64 
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The length of the SMA polymer chain depends on the styrene to maleic acid ratio. The 
SMA used in this research was a 2:1 ratio with a molecular weight of 7500 g/mol, this 
gives a polymer chain length of ~24 monomeric units. For the purpose of this research 
the assumption was made that one SMA polymer chain produces one nanodisc. 
 
3.8.2. DLS average intensity particle size distribution 
The average intensity particle size distribution is a well-known technique for the 
determination of particle size. This technique is the most accurate to determine the size 
of the SMALPs as it measures hydrodynamic diameter as  particle diffuses within a 
fluid.65 DLS was used to establish the average intensity particle size distribution to 
determine if the SMALPs successfully formed. The E.coli SMALPs intensity distribution 
resulted in two peaks, one around 10 nm, that indicates that the nanodiscs have 
formed and another 100 nm, indicating that another larger particle may be present, 
(Figure 17).  In this set of results the size of DMPC SMALPs were also investigated, 
and resulted in two peaks, one around 10 nm, that indicates that the nanodiscs have 
formed and another smaller one around 100 nm,(Figure 18). This as previously 
mentioned may be due to aggregation, or dust particles.  
 





Figure 18: Average intensity particle size distribution of DMPC SMALPs (412 µM). 
 
The results from the average intensity particle size distribution of E.coli SMALPs (326.6 
µM) and DMPC SMALPs (412 µM) was suspended in phosphate buffer pH 7.4, and 
calculated from 9 DLS runs at 298 K. Error given is the standard error of the mean. 
 
3.8.3. DLS Number weighted particle size distribution 
To obtain more detail about the size of the nanodiscs, the number distribution was 
investigated, which reports the smallest size measured in solution. This data is 
supporting information to the average intensity particle size distribution, and is not a 
viable way to measure the size of particles alone.63  
The Number weighted particle size distribution was determined to further investigate 
the particle size of the SMALPs. The same set of DLS data used in plotting Figure 
17/18, also reports the average number weighted particle size distribution as previously 
mentioned. All of the particles in solution were within the size range of ~5 nm to 12 nm, 
(Figure 19/20) which was coherent with the size reported in literature. Both graphs do 
not display the larger aggregates, which were present with the intensity weighted 
graphs. This is due to the number contribution from the larger aggregates was so small 
(<0.001%) that it is no longer considered relevant and therefore not displayed. This 
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further confirms that the peak on Figure 17, of 100-1000 nm was from an anomaly 
within the sample.  
 
Figure 19: Average number weighted particle size distribution of E.coli SMALPs (326.6 µM). 
 
Figure 20: Average number weighted particle size distribution of DMPC SMALPs (412 µM). 
 
Results from the number weighted particle size distribution of E.coli SMALPs (326.6 µM) 
and DMPC SMALPs (412 µM)  suspended in phosphate buffer pH 7.4, and calculated 
from 9 DLS runs at 298 K. Error given is the standard error of the mean. 
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3.8.4. DLS correlation function data 
The correlation function data was determined to establish the uniformity of the sample. 
With the same set of data from used to determine the size.  Correlation data for the 
E.coli SMALPs (Figure 21) shows than the 9 runs were all consistent, and the DMPC 
SMALPs (Figure  22) show only a slight variation in the correlation function, which is 
still considered to be acceptable data. Therefore given the repeatable correlation 
functions, the data collected regarding the size of the particles for both E.coli and 
DMPC SMALPs is credible. 
 
Figure 21: Correlation function data relating for E.coli SMALPs (326.6 µM). 
 




Results from the correlation function data relating to average intensity weighted particle 
size and the average number weighted particle size for  both E.coli SMALPs (326.6 µM) 
and DMPC SMALPs (412 µM), calculated from 9 DLS runs at 298 K. 
3.8.5. Zeta potential  
 
Zeta potential is a measure of magnitude of charges on nanoparticles and provides 
information about particle stability. The zeta potential relates to charged species 
present at the particles surface, that impairs aggregation and/or precipitation,  higher  
magnitude of potential  increases electrostatic repulsion within the colloidal system. 
The more positive or negative the zeta potential is, increases the colloidal stability, a 
value of +/-30 mV indicates good stability. 
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The zeta potential of the SMALPs was measured to determine the stability of their 
structure. The mean zeta potential for the E.coli SMALPs is -47.66 mV, (Figure 23). 
The mean zeta potential for the DMPC SMALPs is -8.50 mV (Figure 24). This shows 
the stability of E.coli SMALPs to be slightly higher than the stability of DMPC SMALPs, 
due to the increased zeta potential and therefore increased colloidal stability.   
The zeta potential determined for DMPC SMALPs is deemed to be fairly unstable with 
a low mean average. The E.coli SMALPs were more stable with a slightly higher mean 
average. Samples that have low zeta potential are coherent with poor physical stability, 
and are more susceptible to aggregation and/or precipitation. 67  As a result the 
SMALPs were regularly checked with DLS to determine whether or not there were any 




Figure 23: Zeta potential data for E.coli SMALPs (326.6 µM). 
 
 
Figure 24: Zeta potential data for DMPC SMALPs (412 µM). 
 
The graphs display the results for zeta potential data for E.coli SMALPs (326.6 
µM) with a mean average of -47.66 mV and DMPC SMALPs (412 µM) with a mean 
average of   -8.50 mV, calculated from 10 DLS runs at 298 K.  Error given is the 





3.8.6. TEM Imaging of SMALPs 
The next step to investigate the formation of nanodiscs was to visualise them using 
TEM. The negatively stained uranyl acetate TEM results showing images of E.coli 
SMALPs in Figure 25. The image has been enlarged with  red circles, indicating the 
spherical shapes.(Figure 26 ) Visual evidence of spherical structures was observable 
and coherent with the size of reported nanodiscs ~10 nm, this further confirms the 
presence of formed SMALPs. 
 
 










TEM results shows images of DMPC SMALPs in Figure 27. The image has been enlarged 
with  red circles, indicating the spherical shapes (Figure 28).  Visual evidence of spherical 
structures was observable and coherent with the size of reported nanodiscs ~10 nm, this 
further confirms the presence of formed SMALPs. 
 
 
Figure 27: TEM image of DMPC SMALPs sample. Scale bar =100 nm 
 
 








 NMR Results and Discussion  3.9.
3.9.1. Hydrogen preferential binding mode 
The most abundant lipid component of E.coli lipid extract is PE lipid; it is hypothesised 
that the SSAs can bind to PE SMALPs more than to the PC SMALPs. This is due to the 
unhindered electrostatic interactions of the PE phospholipid headgroups. This is useful 
as the SSAs will have selectively towards bacterial membranes, and not towards 
mammalian eukaryotic cells.  
The electrostatic interactions include hydrogen bonding. The hypothesised HBD and 
HBA headgroup binding modes for SSA with PE, can be seen in, Figure 29. Here the 
SSA can interact with the phospholipid headgroup, through hydrogen bond 
associations to induce antimicrobial activity, causing membrane disruption on the 
surface of the cytoplasmic membrane, which can then lead to cell death.  
The hypothesised HBD and HBA headgroup binding modes for SSA with PC can be 
seen in, Figure 30. The SSA is not able to form all of the hydrogen bonds and interact 
with the phospholipid headgroup. This is due to three methyl groups present that 
sterically hinder the electrostatic interactions;19 this impedes the hydrogen bonding to 





Figure 29: Hypothesised unhindered HBA and HBD preferential binding modes with SSA: PE 
headgroup. 
              
Figure 30: Hypothesised sterically hindered electrostatic interactions and HBA and HBD 
preferential binding modes with SSA: PC headgroup. 
 
3.9.2. NMR 1H 1D DMPC and E.coli [SMALPs]/ [Compound 1] 
NMR was an ideal technique for observing the interactions between the SSAs and the 
SMALPs.42 To investigate the interactions of 1-3, with phospholipid nanodiscs, 1H NMR 
titration studies with SMALPs were conducted. All of the results for 1H 1D NMR 
comparison show the change in intensity % for compounds 1-3. The concentration of 
the SMALPs (guest) was increased against compounds 1, 2 and 3, (host) (100 µM) 
(550µL) and represented as a molar ratio [ SMALPs]/[Compound 1-3]  which permitted 
comparable results. This technique was based on observing the SSA in its free 
58 
 
unbound state, to the SSA-SMALP bound state. This was observed by NMR with the 
resonance frequency which is directly proportional to the strength of the magnetic field 
applied; therefore the electromagnetic frequency signal is the same as the magnetic 
field at the nucleus of the complex being observed. 
To determine the interactions of the SSA to the SMALPs, a series of NMR titration 
studies were performed. The spectra were phased, base line corrected and calibrated 
to the centre of the solvent peak. Within the data the optimal peak to monitor was 
selected and determined. The aromatic peaks of the compounds from the NMR spectra 
were selected, and monitored for peak reduction. This indicates that the compound is 
binding to the nanodiscs, creating larger structures and this causes the peak to 
eventually become very broad and can no longer be detected by NMR. The aromatic 
peaks were deemed to be the most reliable as they did not readily exchange 
hydrogens with the solvent (water), which happens with the N-H group of the molecule. 
Only one peak from the aromatic region from spectra was analysed, it is noted that 
analysing  two or more peaks average intensity, may have produced less noisy more 
reliable data. The spectra of SSA alone does not display any evidence of 
supramolecular complexes formed, this is due to the low concentrations. However with 
the addition of SMALPs the peaks observed become less intense and broader peaks 
appear suggesting that larger supramolecular complexes are being formed, this can be 
seen in the NMR stack plots below. Tables with the full sets of the data collected for the 
1H NMR titration studies and 1H 1D NMR Spectra for compound 1-3 (100 µM) can be 
found in the appendices.  
The first set of results were the change in intensity % against the molar ratio of DMPC 
and E.coli [SMALPs]/ [Compound 1],  (Figure 31). All of the Data for the NMR results 
were plotted in excel. The first point on the graph represents 1H 1D NMR data of the 
SSA in its free unbound state. The plotted graph shows successfully binding to the 
SMALPs; this was confirmed through the decrease in intensity %, which is a direct 
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effect of part of the SSA being in a bound state and no longer detectable by NMR. 
However this drop in intensity was similar for both the E.coli and DMPC compositions, 
this was seen with the plotted data. This indicates that they both have a similar degree 
of association, which was not expected, further investigative methods were required.   
1H 1D NMR graph is for clarification of the lower value molar ratio [SMALPs]/ 













The concentrations of the molar ratios chosen for the stack plots can be found in Table 
2. Full set of measurements and 1H 1D NMR Spectra for compound 1 (100 µM) can be 
found in the appendices. 
 Due to the concentration of the SMALPS being slightly different the molar ratios also 
differ slightly. The concentration added of SMALPs was consistent however the volume 
was slightly different. In retrospection it would have been better to dilute down or 
concentrate the SMALPs to the same concentrations prior to starting the NMR 
titrations.   
Table 2:: Colour scheme for NMR spectra stack plots with matching molar measurement.  
 
NMR spectra stack plot for E.coli [SMALPs]/ [Compound 1] (Figure 33) arrow indicates 
peak observed at 7.6651 ppm and DMPC [SMALPs]/ [Compound 1] (Figure 34) arrow 





H 1D NMR spectra stack plot for E.coli [SMALPs]/ [Compound 1]  












H 1D NMR spectra stack plot for DMPC [SMALPs]/ [Compound 1] 
 
The NMR stack plots coincided with the graphs, displaying that the addition of the 
SMALPs with compound 1 has less self-association than with other compounds 
studied. Further studies would include increasing the concentration of SMALPs added.   
 
3.9.3. NMR 1H 1D DMPC and E.coli [SMALPs]/ [Compound 2] 
The next set of titration results were the change in intensity against the molar ratio of 
DMPC and E.coli [SMALPs]/[Compound 2], (Figure 35)  The first point on the graph 
represents 1H 1D NMR data of the SSA in its free unbound state, the same as in 3.9.2. 
The plotted graph shows successfully binding to the SMALPs; this was confirmed 
through the decrease in intensity %, which is a direct effect of the SSA being in a 
bound state and no longer detectable by NMR, hence only the free unbound SSA is 
detectable.  
As expected the drop in intensity was greater for E.coli than for DMPC SMALPs, this 
was seen with the plotted data. In this experiment the same SSA and the same SMA 
copolymer was present. The only different components were the phospholipids. This 
indicates that the difference in intensity % is directly related to the electrostatic 
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interactions. More precisely the hindered hydrogen bonding, between the SSA and the 
PC lipids due to three methyl groups present that sterically hinders the electrostatic 
interactions, as discussed in 3.9.1. See Figure 36, 1H 1D NMR graph for clarification of 
the lower value molar ratios [ SMALPs]/[Compound 2] which displayed the same trend 








H 1D NMR results for DMPC and E.coli [SMALPs]/ [Compound 2] zoomed in. 
NMR spectra stack plot for E.coli [SMALPs]/ [Compound 2] (Figure 37) arrow indicates 
peak observed at 7.9684 ppm and DMPC [SMALPs]/ [Compound 2] (Figure 38) arrow 
indicates peak observed at 7.9727 ppm. The concentrations of the molar ratios applied 
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in  the stack plots can be found in Table 2 in section 3.9.2. Full set of measurements 









H 1D NMR spectra stack plot for DMPC [SMALPs]/ [Compound 2] 
 
The NMR stack plots coincide with the graphs, displaying the addition of the SMALPs 
with compound 2. Here self-association can be seen with the peaks becoming broader, 
indicating the nanodiscs were binding to the compound.  
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3.9.4. NMR 1H 1D DMPC and E.coli [SMALPs]/ [Compound 3] 
The last set of 1H 1D titration results was the change in intensity against the molar ratio 
of DMPC and E.coli [SMALPs]/ [Compound 3] (Figure 39). The first point on the graph 
represents 1H 1D NMR data of the SSA in a free unbound state, the same as in 3.9.2. 
The graph shows a clear difference in the binding associations, between the two types 
of SMALPs. These results were as expected with the drop in intensity % was greater 
for E.coli than for DMPC SMALPs, as can be seen with the plotted data. Similar results 
were seen and discussed in 3.9.3 with compound 2, however, it’s noted that the drop in 
intensity % was considerably less, than the previous results with compound 2, 
indicating less electrostatic interactions between the SSA-SMALPs. See Figure 40 for 
1H 1D NMR graph for clarification of the lower value molar ratios [SMALPs]/ 
[Compound 3] which displayed the same trend. 
 
 






H 1D NMR results for DMPC and E.coli [SMALPs]/ [Compound 3] zoomed in 
 
NMR spectra stack plot for E.coli [SMALPs]/ [Compound 3] (Figure 41) arrow indicates 
peak observed at 8.1372 ppm and DMPC [SMALPs]/ [Compound 3] (Figure 42) arrow 
indicates peak observed at 8.1369 ppm. The concentrations of the molar ratios applied 
in the stack plots can be found in Table 2 in section 3.9.2. Full set of measurements 












H 1D NMR spectra stack plot for DMPC [SMALPs]/ [Compound 3] 
 
The NMR stack plots coincided with the graphs, displaying the addition of the SMALPs 
with compound 3. Here self-association can be seen with the peaks becoming smaller, 
indicating the nanodiscs were binding to the compound, resulting in less free SSA 
being detected. 
3.9.5. NMR 1H 1D E.coli SMALPs [SMALPs]/ [Compound (1) (2) (3)] 
The next set of results was a comparison with E.coli SMALPs against compounds 1-3, 
from the titrations in 3.9.2-3.9.4. These were compared to determine how the different 
SSAs bind with a bacterial membrane.  
The results in the graph, (Figure 43) display the change in intensity % for each 
compound when interacting with the SMALP. All of the SSAs had a change in peak 
intensity from the NMR spectra. This peak reduction and broadening, indicates 
electrostatic binding interactions. Compound 1, had the least amount of change in 
intensity %, up to ~20% drop, compound 2, displayed the greatest decrease in intensity 
with a decrease of around 95%, and compound 3, had a change in intensity % up to 
60% drop. The differences between compounds 2-3 were as expected, due to the 2-
phenylbenzo[d]thiazole on 3 in the ortho position, hindering the HBA/HBD groups 
between the urea and the phosphate. In 2 the 2-phenylbenzo[d]thiazole is in the para 
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position, allowing for unhindered HBA/HBD interactions. Finally 1, has a trifluoromethyl 
in the para position, this compound was expected to display similar associations as 2 
with unhindered HAD/HBD. However this data indicates that the trifluoromethyl did not 
contribute to SSA-SMALP binding, in the same way as 2-phenylbenzo[d]thiazole. See 
Figure 44, 1H 1D NMR graph for clarification of the lower value molar ratios E.coli 









H 1D NMR results for E.coli [SMALPs]/ [Compound (1) (2) (3)] zoomed in 
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 3.9.6. NMR 1H 1D DMPC [SMALPs]/ [Compound (1) (2) (3)] 
The next set of results was a comparison with DMPC SMALPs against compounds 1-3, 
from the titrations in 3.9.2-3.9.4. These were compared to determine how the different 
SSAs bind with a mammalian membrane. The results in the graph, (Figure 45) display 
the change in intensity for each compound when interacting with the SMALP. All of the 
SSAs had a change in intensity with a similar pattern to the results discussed in 3.9.5, 
however these decreases in intensity, were not as high as the ones with E.coli 
SMALPs due to hindered interactions of the PC phospholipid headgroup, as previously 
discussed.  
Compound 1, has the least amount of change in intensity of ~20%, compound 2, 
displayed the greatest decrease in intensity with a decrease of around 70%, and 
compound 3, has a change in intensity of ~30%. The difference in results between 1-3, 
follows the same trend as in 3.9.5 and has been previously discussed. 
See, Figure 46, 1H 1D NMR graph for clarification of the lower value molar ratios 
DMPC [SMALPs]/[Compound (1)(2)(3)] which shows that 1 and 3 had a similar 
decrease in intensity, indicating higher concentration of SMALPs may have been 
needed to establish the differences in binding. 
 






H 1D NMR results for DMPC [SMALPs]/ [Compound (1) (2) (3)] zoomed in 
3.9.7. NMR 1H CPMG DMPC and E.coli [SMALPs]/ [Compound 1] 
The last experiment was CPMG NMR, with the aim to further investigate the 
interactions of 1-3, with phospholipid nanodiscs. With CPMG NMR the spin-spin T2 
relaxation time is measured and applied to a series of spin-echo pulse elements. The 
T2 relaxation is caused by transient magnetic fields due to molecular motion. This 
detects the interactions of the ligand with the nanodisc, these interactions cause de-
phasing as the protons can no longer be completely refocused. This decay in signal 
indicates successful ligand binding interactions. In practice, a CPMG spectrum of the 
SSA sample was taken and compared to the CPMG spectrum of the ligand with the 
SMALPs sample. The more the signal decays the more the compound-SMALP 
interactions were occurring. This was indicated by broadening and reduction in the 
peak signals.68,69 
To determine the interactions of the SSA to the SMALPs, the aromatic peaks of the 
compounds from the NMR spectra were selected, and monitored for peak reduction, for 
reasons previously discussed. This indicates that the SSA was interacting with the 
nanodiscs, similar to the 1H NMR experiments. However this experiment was different 
as the peak reduction on the NMR spectra relates to all of the SSA that has interacted 
with the SMALP, and not just the bound in real time. This was measured through the 
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change in T2 relaxation time, which is a result from successful binding within the 
sample.68 
All of the results for 1H CPMG NMR comparison show the change in intensity % for 
compound 1-3 (host) at 100 µM, the concentration of  SMALPs (guest) was increased 
the data was represented as a molar ratio [ SMALPs]/[Compound 1-3] PB/5 % D20 
solution (298 K). Tables with the full sets of the data collected for the CPMG NMR 
titration studies are located in the appendices. 
The first set of CPMG results show the change in intensity % against the molar ratio of 
DMPC and E.coli [SMALPs]/ [Compound 1],  (Figure 47).  The first point on the graph 
represents CPMG NMR data of the SSA with no SMALPs.  The plotted graph shows 
successfull interactions with to the SMALPs; this was confirmed through the decrease 
in intensity. Here there was a clear difference in the interactions with the higher 
concentration of SMALPs, with the E.coli SMALPs interacting more than the DMPC 
SMALPs, as can be seen with the plotted data. On examination of the lower molar ratio 
there is little difference between the E.coli binding and the DMPC SMALPs, however 
the E.coli has a more consistent interactions with the compound. Graph 1H CPMG NMR 











H CPMG NMR results for DMPC and E.coli [SMALPs]/ [Compound 1] Zoomed in 
 
NMR spectra stack plot for E.coli [SMALPs]/ [Compound 1] (Figure 49) arrow indicating 
peak observed at 7.6698 ppm and DMPC [SMALPs]/ [Compound 1] (Figure 50) arrow 
indicating peak observed at 7.6797 ppm. The concentrations of the molar ratios included 
in the stack plots were from 0 (yellow) to 1.229 (blue) for E.coli and 0 (yellow) to 1.330 
(blue) for DMPC, full set of molar ratios included can be found in Table 2 in section 3.9.2. 
 
 
Figure 49: CPMG NMR spectra stack plot for E.coli
 




Figure 50: CPMG NMR spectra stack plot for DPMC [SMALPs]/ [Compound 1] 
 
The NMR stack plots coincide with the graphs, displaying the addition of the SMALPs 
with compound 1. Here self-association can be seen with the peaks becoming smaller, 
indicating the nanodiscs were binding to the compound, resulting in a reduced amount 
SSA being detected. 
 
3.9.8. NMR 1H CPMG DMPC and E- coli [SMALPs]/ [Compound 2] 
The next set of titration results were for 1H CPMG NMR comparison showing the 
change in intensity for compound 2 (host) at 100 µM (Figure 51) The graph below 
shows that initially the differences in binding, was E.coli interacting and binding more 
than the DMPC SMALPs, but the PC SMALP intensity decreased  much faster and with 
lower concentrations, of ~0.05 molar ratio. This represents that compound 2 was 
binding to SMALPs even at low concentrations leading to a rapid decay in the 
electromagnetic signal. These results were not coherent with the 1H 1D NMR results 
discussed in 3.9.3 as in the previous studies, where the DMPC SMALP results 
continued to have a lower drop in intensity % than the E.coli, however this measured 
just the bound state resulting in broader peaks and the CPMG measured the T2. Here 
the DMPC SMALPs have interacted with the SSA, however these electrostatic 
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interactions may be weaker binding than with E.coli SMALPs, further studies were 





H CPMG NMR results for DMPC and E.coli [SMALPs]/[Compound 2] 
NMR spectra stack plot for E.coli [SMALPs]/ [Compound 2] (Figure 52) arrow indicates 
peak observed at 7.961 ppm and DMPC [SMALPs]/ [Compound 2] (Figure 50) arrow 
indicates peak observed at 7.9730 ppm. 
 
 The concentrations of the molar ratios included in the stack plots for compound 2, are 
located in Table 3, the full set are located in the appendices. 















Figure 52: CPMG NMR spectra stack plot for E.coli
 
 [SMALPs]/ [Compound 2] 
 
 
Figure 53: CPMG NMR spectra stack plot for DPMC [SMALPs]/ [Compound 2] 
 
The NMR stack plots coincided with the graphs, displaying the addition of the SMALPs 
with compound 2. Here self-association was seen with the peaks becoming broader 
and less intense, indicating the nanodiscs were binding to the compound.  
 
3.9.9. NMR 1H CPMG DMPC and E.coli [SMALPs]/[Compound 3] 
The last set of results for 1H CPMG NMR were a comparison showing the change in 
intensity for compounds 3 (host) at 100 µM) (Figure 54) 
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The graph shows a clear difference in the interactions, between the two types of 
SMALPs, with an increased decay in the SSA peak intensity, when interacting with 
E.coli. These results were as expected with the drop in intensity, greater for E.coli than 
for DMPC SMALPs, as can be seen with the plotted data and were coherent with the 
1H 1D NMR results with 3. How the compounds interact with the SMALP has been 
previously discussed with similar results 9.3-9.4. See Figure 55, for 1H CPMG NMR 
graph for clarification of the lower value molar ratios [SMALPs]/[Compound 3], which 








H CPMG NMR results for DMPC and E.coli [SMALPs]/[Compound 3] Zoomed in 
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NMR spectra stack plot for E.coli [SMALPs]/ [Compound 3] (Figure 56) arrow indicates the 
peak observed at 8.1372 ppm and DMPC [SMALPs]/ [Compound 3] (Figure 57) arrow 
indicates the peak observed at 8.1369 ppm. The concentrations of the molar ratios 
included in the stack plots were from 0 (yellow) to 1.229 (blue) for E.coli and 0 (yellow) to 




Figure 56: CPMG NMR spectra stack plot for E.coli
 
 [SMALPs]/ [Compound 3] 
 




The NMR stack plots coincided with the graphs, displaying the addition of the SMALPs 
with compound 3. Here self-association was seen with the peaks becoming broader, 
indicating the nanodiscs were binding to the compound, with the E.coli: compound 3, 
the peaks ~ 7.5 ppm became so broad they can no longer be detected. 
 
3.9.10. NMR 1H CPMG E.coli SMALPs [SMALPs]/[Compound (1)(2)(3)] 
The next set of results displays a comparison with E.coli SMALPs against compounds 
1-3, from the titrations in 3.9.7-3.9.9. These were compared to determine how the 
different SSAs bind with a bacterial membrane.  
The results in the graph, (Figure 58) display the change in intensity for each compound 
when interacting with the SMALP. All of the SSAs had a  change in peak intensity from 
the NMR spectra. This peak reduction and broadening, indicates electrostatic 
interactions and self-associations between the SSA and SMALPs. Compound 1, has 
the least amount of change in intensity % of ~ 40%, compound 2, displayed a rapid 
decay of the signal, indicating binding and the formation of supramolecular complexes. 
Compound 3, had a change in intensity % of ~95%. The differences between 
compounds 2-3 were as expected, and were coherent with the 1H 1D NMR data, in 
3.9.6 how the compounds interacted with the SMALPs has been previously discussed 
with similar results 3.9.3-3.9.4. See Figure 59, for 1H CPMG NMR graph for clarification 











H CPMG NMR results for E.coli [SMALPs]/[Compound (1)(2)(3)]Zoomed in 
 
3.9.11. NMR 1H CPMG DMPC [SMALPs]/[Compound (1)(2)(3)] 
The last comparison was results for 1H CPMG NMR showing the change in intensity for 
each compound 1-3, against PC SMALPs from the titrations in 3.9.7-3.9.9.  
The results in the graph (Figure 60) show a clear difference in the interactions between 
the compounds, with compound 2, showing a larger decrease in intensity %.  These 
results follow trend with the results in 3.9.10, however in this set of results the change 
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in intensity % was smaller than with the E.coli results. This was expected and coherent 
with the rest of the NMR analysis within this study. How the molecular structures, 
influence the interactions has been previously discussed in 3.9.5. See Figure 61, for 1H 
CPMG NMR graph for clarification of the lower value molar ratios [ 
SMALPs]/[Compound (1)(2)(3)]. 
NMR results were coherent with this hypothesis as the results for both the 1H CPMG 
and 1H 1D, exhibit a more interactions towards the E.coli SMALPs when compared to 
the binding with the DMPC SMALPs with compound 2-3. The only exception was NMR 
1H 1D with compound 1, where the binding appeared to be similar, however this was 
an anomaly when compared to the rest of the data. Further investigation was needed 
at higher concentrations and/or more scans to improve the signal to noise ratio to 











H CPMG NMR results for DMPC [SMALPs]/[Compound (1)(2)(3)] zoomed in 
 
3.9.12. Secondary binding modes 
The NMR titration results displayed that some of the plotted intensity results were non-
uniform, and did not always follow trend. This could be due to many factors, the 
simplest one could be a mixing error, or the sample may have needed more time to 
equilibrate, as no extra time was given, however this can have repercussions as the 
compounds antimicrobial activity may be time dependant, leading to a sample with only 
the compound and disassembled nanodiscs. The non-uniform data may also have 
been improved by analysing the average of more than just one aromatic peak, again 
further studies were needed. 
A hypothesis for the non-uniform intensity results can be due to multiple interactions 
with secondary hydrogen binding sites of the SMALPs. The secondary site includes the 
hydrogen bond donating of the urea moiety of the compound.  
An example of this is with the PE SMALPs, where adding the SMALPs to the 
compound; the sulfonate moiety will primarily bind to the amine.  Once most of the 
primary binding sites are full, causing   complete saturation of the binding site, 38 then 
the compound will start to bind in other places. These include HBD/HBA interactions 
with the urea moiety and phosphate as seen in Figure 29. These contribute towards the 
81 
 
secondary weaker binding sites.  With the addition of more SMALPs the compound will 
be attracted to the new primary binding sites and will momentarily be free in solution, 
resulting in non-uniform data with an increase in intensity.   
The PC SMALPs with the amphiphilic compounds also exhibit some non-uniform data, 
this can be attributed to other non-covalent bond interactions which have been 
described in literature and include electrostatics, π−π stacking, charge transfer and 
hydrogen bond interactions.70 These interactions not only occur with the compound-
SMALP binding but also with compound self-association.  
3.9.13. SSA structure-activity 
In the literature previous studies with self-associating amphiphiles have revealed that 
changing compound composition affects antimicrobial action. All of the self-associating 
molecules in this study, were synthesised from the same general structure as seen in 
the literature, with urea oxygen in the hydrophobic region, sulfonate in the hydrophilic 
region and with TBA as a counter cation. Keeping these functionalities the same 
focused this study on the modifications of the constituents attached to the benzene ring 
only. Compound 2 and compound 3 with 2-phenylbenzo[d]thiazole displayed more 
interactions towards the E.coli SMALPs, the position of this R group played an 
important role, with the 2-phenylbenzo[d]thiazole in the para position resulted in 
enhanced activity when compared to the ortho position. This change in activity is 
directly related to the 2-phenylbenzo[d]thiazole hindering the hydrogen bond donating 
functionality of the urea oxygen when in the ortho position. This reveals that   urea is 
vital for hydrogen bonding and therefore vital for antimicrobial activity.  
When comparing selectivity towards the bacterial membranes and mammalian 
membranes, the results have shown that the compounds will interact and accumulate 
on the surface with the bacterial membranes more intensely than the mammalian 
membranes. This was seen through the 1H 1D NMR studies, where nearly all of the 
compounds displayed a greater change in intensity with E.coli SMALPs, indicating that 
82 
 
the compounds were binding to the SMALP. These compounds will also aggregate on 
the surface of the E.coli SMALP due to their self-associating properties; this was 
observed with similar self-associating molecules in literature, where they found that 
self-associated structures is imperative for effective drug delivery to the bacterial cell.56 
The 1H CPMG results displayed the same pattern as the 1H 1D study, with the 
broadening and reduction in the intensity of the signals, with increasing SMALP to 
compound interactions. The resulting peaks in this experiment were much smaller than 
with the 1H 1D study, this was due to the signal decay upon the interaction of the 
SMALPs with the compound. 68  
The PC SMALPs resulted in fewer binding interactions, which as previously mentioned 
may be due to electrostatic interactions other than the phospholipids headgroup with 
the sulfonate. This was not favourable due to the three methyl groups attached to the 
amine, leading to electrostatic hindrance. However weaker binding interactions were 
still observed, these are thought to be insufficient to disrupt the structure of the 













4. Overall Conclusions 
In conclusion, this preliminary research investigated the binding interactions between 
supramolecular self-associating molecules, and the cell membrane. The model 
membranes were formed with a SMA co-polymer that solubilises a patch of 
phospholipid bilayers in to nanodiscs.  This allowed for the formation of nanodiscs with 
different lipid compositions, mimicking the bacterial cells and mammalian cells. The 
nanodiscs were characterised through DLS, TEM and quantified. The binding 
associations between three self-associating compounds and the model membranes 
were investigated through 1H 1D and CPMG NMR analysis. The results indicate that 
the compounds structure affects the binding with the nanodiscs.  The compounds were 
all identical with the same HBD/HBA functionalities, with the only one different 
constituent attached to a benzene ring. This verified that the change in binding 
observed towards the model membranes was a direct result of the constituent. The 
position of the constituent affected the hydrogen bonding, thus affecting its 
antimicrobial properties. The results reveal that that the all three compounds exhibit 
selective binding towards E.coli, when compared to the binding of mammalian cells. 
This shows potential for their use as future antimicrobial agents, aiding in the fight 
against antimicrobial resistance.     
Further work  
In this study only three compounds were investigated, which form part of a family of 
over 65 molecules.  Further work would include the binding studies with other 
amphiphilic compounds against E.coli and against other bacterial strains. Further work 
with the compounds presented in this study would include fluorescence anisotropy 
binding studies, on the fluorescent molecules compound 2 and compound 3 and 
confocal microscopy to visualise the compounds interacting with the nanodiscs, which 
will help determine if the compounds are bacteriostatic or bactericidal. Both of these 
methods of investigation were initialised but due to time constraints were not realised.  
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Figure 1: NMR 
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Figure 2: NMR 
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Figure 3: NMR 
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H 1D of Compound 3 
 
Table displaying concentrations used in NMR titrations 
Table 2: Molar ratio of compounds 1-3 to SMALP 
 
SSA (µM) E.coli SMALP (µM) Molar ratio SSA (µM) DMPC SMALP (µM) Molar ratio
100.0 0.0 0.000 100.0 0.0 0.000
99.7 0.2 0.002 99.5 0.2 0.002
99.3 0.4 0.004 99.0 0.4 0.004
99.0 0.6 0.006 98.6 0.6 0.006
98.7 0.8 0.008 98.1 0.8 0.008
98.3 1.0 0.010 97.6 1.0 0.010
97.5 1.5 0.015 96.5 1.5 0.016
96.8 2.0 0.021 95.4 2.0 0.021
95.2 3.0 0.032 93.2 3.0 0.032
93.7 4.0 0.043 91.1 4.0 0.044
93.4 6.0 0.064 90.7 6.0 0.066
93.1 8.0 0.086 90.3 8.0 0.089
92.8 10.0 0.108 89.9 10.0 0.111
92.1 15.0 0.163 89.0 15.0 0.169
91.4 20.0 0.219 88.0 20.0 0.227
90.7 25.0 0.276 87.1 25.0 0.287
87.4 50.0 0.572 82.7 50.0 0.605
84.3 75.0 0.890 78.8 75.0 0.952
81.4 100.0 1.229 75.2 100.0 1.330
90 
 
NMR 1H 1D Data Tables 
 
 
Table 2: NMR 1H 1D Data Table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for E.coli [SMALPs}/[Compound 1] 
 
E.coli [SMALPs]/[Compound 1] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 244736.26 7.6651 0.00 100 
2 0.002 241098.97 7.6654 -3637.29 99 
3 0.004 243217.25 7.6654 -1519.01 99 
4 0.006 242727.78 7.6652 -2008.48 99 
5 0.008 234072.01 7.6652 -10664.25 96 
6 0.010 196846.70 7.6649 -47889.56 80 
7 0.015 217040.73 7.6652 -27695.53 89 
8 0.021 211948.38 7.6652 -32787.88 87 
9 0.032 204340.75 7.6650 -40395.51 83 
10 0.043 229346.12 7.6654 -15390.14 94 
11 0.064 214958.92 7.6654 -29777.34 88 
12 0.086 214903.08 7.6656 -29833.18 88 
13 0.108 214127.42 7.6654 -30608.84 87 
14 0.163 208837.77 7.6648 -35898.49 85 
15 0.219 223973.19 7.6649 -20763.07 92 
16 0.276 195888.98 7.6653 -48847.28 80 
17 0.572 209213.67 7.6650 -35522.59 85 
18 0.890 202843.75 7.6648 -41892.51 83 













Table 3: NMR 1H 1D data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for DMPC [SMALPs}/[Compound 1] 
 
DMPC [SMALPs]/[Compound 1] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 237445.73 7.6664 0 100 
2 0.002 254662.36 7.6654 17216.63 107 
3 0.004 204817.79 7.6653 -32627.94 86 
4 0.006 214667.22 7.6656 -22778.51 90 
5 0.008 200555.42 7.6651 -36890.31 84 
6 0.010 190162.27 7.6652 -47283.46 80 
7 0.016 190693.14 7.6652 -46752.59 80 
8 0.021 192061.3 7.6653 -45384.43 81 
9 0.032 215845.3 7.6654 -21600.43 91 
10 0.044 196390.48 7.6652 -41055.25 83 
11 0.066 227421.84 7.6655 -10023.89 96 
12 0.089 196359.63 7.6653 -41086.1 83 
13 0.111 183757.97 7.6653 -53687.76 77 
14 0.169 183014.91 7.6653 -54430.82 77 
15 0.227 196913.95 7.6652 -40531.78 83 
16 0.287 202091.28 7.6647 -35354.45 85 
17 0.605 200134.72 7.6644 -37311.01 84 
18 0.952 207774.38 7.6634 -29671.35 88 
















Table 4: NMR 1H 1D data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for E.coli [SMALPs}/[Compound 2] 
 
E.coli [SMALPs]/[Compound 2] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 251245.08 7.9684 0.00 100 
2 0.002 234486.59 7.9686 -16758.49 93 
3 0.004 171990.09 7.9682 -79254.99 68 
4 0.006 117466.96 7.9682 -133778.12 47 
5 0.008 195921.41 7.9672 -55323.67 78 
6 0.010 155575.69 7.9639 -95669.39 62 
7 0.015 189914.87 7.9685 -61330.21 76 
8 0.021 138743.94 7.9684 -112501.14 55 
9 0.032 152925.31 7.9703 -98319.77 61 
10 0.043 135405.82 7.9714 -115839.26 54 
11 0.064 107220.88 7.9697 -144024.20 43 
12 0.086 97050.81 7.9688 -154194.27 39 
13 0.108 82492.14 7.9669 -168752.94 33 
14 0.163 74545.23 7.9666 -176699.85 30 
15 0.219 60342.98 7.9669 -190902.10 24 
16 0.276 53912.08 7.9652 -197333.00 21 
17 0.572 39910.31 7.9655 -211334.77 16 
18 0.890 14594.62 7.9621 -236650.46 6 

























Table 5: NMR 1H 1D data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for DMPC [SMALPs}/[Compound 2] 
 
DMPC [SMALPs]/[Compound 2] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 193787.45 7.9727 0 100 
2 0.002 194069.8 7.9729 282.35 100 
3 0.004 143133.77 7.9729 -50653.68 74 
4 0.006 151515.98 7.9709 -42271.47 78 
5 0.008 151192.83 7.9716 -42594.62 78 
6 0.010 129608.33 7.9733 -64179.12 67 
7 0.016 118949.76 7.9697 -74837.69 61 
8 0.021 109761.05 7.9694 -84026.4 57 
9 0.032 117818.23 7.9693 -75969.22 61 
10 0.044 93345.38 7.9709 -100442.07 48 
11 0.066 90259.34 7.9675 -103528.11 47 
12 0.089 93874.86 7.965 -99912.59 48 
13 0.111 102988.57 7.9616 -90798.88 53 
14 0.169 87758.78 7.9617 -106028.67 45 
15 0.227 76413.78 7.9599 -117373.67 39 
16 0.287 70673.84 7.9591 -123113.61 36 
17 0.605 64816.16 7.9593 -128971.29 33 
18 0.952 59487.62 7.9592 -134299.83 31 


















Table 6: NMR 1H 1D data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for E.coli [SMALPs}/[Compound 3] 
 
E.coli [SMALPs]/[Compound 3] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 224544.22 8.1372 0.00 100 
2 0.002 199405.38 8.1370 -25138.84 89 
3 0.004 143059.06 8.1372 -81485.16 64 
4 0.006 138289.80 8.1367 -86254.42 62 
5 0.008 139316.47 8.1373 -85227.75 62 
6 0.010 142956.26 8.1371 -81587.96 64 
7 0.015 117296.56 8.1376 -107247.66 52 
8 0.021 112258.34 8.1370 -112285.88 50 
9 0.032 139628.79 8.1378 -84915.43 62 
10 0.043 132393.02 8.1375 -92151.20 59 
11 0.064 135936.83 8.1383 -88607.39 61 
12 0.086 136942.29 8.1387 -87601.93 61 
13 0.108 124746.29 8.1386 -99797.93 56 
14 0.163 131747.38 8.1392 -92796.84 59 
15 0.219 95788.56 8.1389 -128755.66 43 
16 0.276 119442.76 8.1396 -105101.46 53 
17 0.572 103788.25 8.1404 -120755.97 46 
18 0.890 112393.28 8.1421 -112150.94 50 

























Table 7: NMR 1H 1D data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for DMPC  [SMALPs}/[Compound 3] 
 
DMPC [SMALPs]/[Compound 3] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 215118.47 8.1369 0 100 
2 0.002 190006.09 8.1371 -25112.38 88 
3 0.004 135703.04 8.136 -79415.43 63 
4 0.006 152144.93 8.1362 -62973.54 71 
5 0.008 149221.8 8.1371 -65896.67 69 
6 0.010 214057.75 8.1375 -1060.72 100 
7 0.016 161672.23 8.1366 -53446.24 75 
8 0.021 130108.61 8.1379 -85009.86 60 
9 0.032 190518.12 8.1382 -24600.35 89 
10 0.044 185307.83 8.1382 -29810.64 86 
11 0.066 180279.04 8.1388 -34839.43 84 
12 0.089 183204.31 8.1392 -31914.16 85 
13 0.111 150270.62 8.1396 -64847.85 70 
14 0.169 188873.94 8.1409 -26244.53 88 
15 0.227 190708.86 8.141 -24409.61 89 
16 0.287 174138.92 8.1416 -40979.55 81 
17 0.605 152823.69 8.1431 -62294.78 71 
18 0.952 156779.75 8.1451 -58338.72 73 



















NMR CPMG 1H Data Tables 
 
 
Table 8: CPMG 1H Data table reporting each peak used to determine the change in 
intensity, and the corresponding molar ratio for E.coli [SMALPs}/[Compound 1] 
 
E.coli [SMALPs]/[Compound 1] 
Peak    Actual    Change in  Change in  
Nam
e Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 49125.72 7.6698 0.00 100 
2 0.002 46798.57 7.6662 -2327.15 95 
3 0.004 47838.05 7.6656 -1287.67 97 
4 0.006 48164.82 7.6656 -960.90 98 
5 0.008 48358.41 7.6655 -767.31 98 
6 0.010 45111.85 7.6654 -4013.87 92 
7 0.015 45607.79 7.6658 -3517.93 93 
8 0.021 44917.25 7.6656 -4208.47 91 
9 0.032 45663.75 7.6656 -3461.97 93 
10 0.043 45829.32 7.6653 -3296.40 93 
11 0.064 43346.40 7.6661 -5779.32 88 
12 0.086 43040.00 7.6638 -6085.72 88 
13 0.108 42319.02 7.6672 -6806.70 86 
14 0.163 41307.73 7.6655 -7817.99 84 
15 0.219 40019.81 7.6657 -9105.91 81 
16 0.276 37797.88 7.6658 -11327.84 77 
17 0.572 36573.70 7.6647 -12552.02 74 
18 0.890 35506.10 7.6654 -13619.62 72 














Table 9: CPMG 1H Data table reporting each peak used to determine the change in 
intensity and the corresponding molar ratio for DMPC [SMALPs}/[Compound 1] 
 
DMPC [SMALPs]/[Compound 1] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 44679.96 7.6797 0 100 
2 0.002 43407.42 7.6802 -1272.54 97 
3 0.004 41681.4 7.6795 -2998.56 93 
4 0.006 43376.17 7.6797 -1303.79 97 
5 0.008 41991.72 7.6797 -2688.24 94 
6 0.010 38147.11 7.6794 -6532.85 85 
7 0.016 42243.82 7.6799 -2436.14 95 
8 0.021 40493.9 7.6796 -4186.06 91 
9 0.032 42922.45 7.68 -1757.51 96 
10 0.044 38932.61 7.6801 -5747.35 87 
11 0.066 42860.55 7.6801 -1819.41 96 
12 0.089 40607.48 7.6796 -4072.48 91 
13 0.111 38849 7.6799 -5830.96 87 
14 0.169 38803.26 7.6795 -5876.7 87 
15 0.227 38601.51 7.6794 -6078.45 86 
16 0.287 36727.07 7.6792 -7952.89 82 
17 0.605 36451.41 7.6788 -8228.55 82 
18 0.952 33913.05 7.6781 -10766.91 76 

















Table 10: CPMG 1H Data table reporting each peak used to determine the change in 
intensity and the corresponding molar ratio for E.coli [SMALPs}/[Compound 2]  
 
E.coli [SMALPs]/[Compound 2] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 31482.46 7.9691 0.00 100 
2 0.002 28355.16 7.9694 -3127.30 90 
3 0.004 15317.93 7.9683 -16164.53 49 
4 0.006 14594.74 7.9684 -16887.72 46 
5 0.008 16301.66 7.9678 -15180.80 52 
6 0.010 14453.92 7.9648 -17028.54 46 
7 0.015 14444.40 7.9687 -17038.06 46 
8 0.021 10556.44 7.9686 -20926.02 34 





Table 11: CPMG 1H Data table reporting each peak used to determine the change in 
intensity and the corresponding molar ratio for DMPC [SMALPs}/[Compound 2] 
 
DMPC [SMALPs]/[Compound 2] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 34764.07 7.973 0 100 
2 0.002 33394.59 7.9867 -1369.48 96 
3 0.004 23565.93 7.9731 -11198.14 68 
4 0.006 18286.94 7.9711 -16477.13 53 
5 0.008 13483.14 7.9725 -21280.93 39 












Table 12: CPMG 1H Data table reporting each peak used to determine the change in 
intensity and the corresponding molar ratio for E.coli [SMALPs}/[Compound 3]  
 
E.coli [SMALPs]/[Compound 3] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 35693 8.1372 0.00 100 
2 0.002 40984.88 8.1387 5291.88 115 
3 0.004 28976.04 8.1373 -6716.96 81 
4 0.006 29516.59 8.1374 -6176.41 83 
5 0.008 27402.12 8.1374 -8290.88 77 
6 0.010 24874.99 8.1375 -10818.01 70 
7 0.015 24335.59 8.1322 -11357.41 68 
8 0.021 21833.54 8.1382 -13859.46 61 
9 0.032 25611.99 8.1373 -10081.01 72 
10 0.043 26520.96 8.1385 -9172.04 74 
11 0.064 3753.56 8.444 -31939.44 11 
12 0.086 22191.14 8.1386 -13501.86 62 
13 0.108 21143.46 8.1381 -14549.54 59 
14 0.163 19381.01 8.139 -16311.99 54 
15 0.219 17861.09 8.1396 -17831.91 50 
16 0.276 17190.13 8.1392 -18502.87 48 
17 0.572 13046.48 8.1411 -22646.52 37 
18 0.890 7271.56 8.1408 -28421.44 20 
19 1.229 3533.98 8.4443 -32159.02 10 
 
 
This set of data had an erroneous point, peak 11 which was excluded from the data 






















Table 13: CPMG 1H Data table reporting each peak used to determine the change in 
intensity and the corresponding molar ratio for DMPC [SMALPs}/[Compound 3] 
 
DMPC [SMALPs]/[Compound 3] 
Peak    Actual    Change in  Change in  
Name Molar Ratio  Intensity ν(F1) [ppm] Intensity Intensity (%) 
1 0.000 34707.62 8.1369 0 100 
2 0.002 32767.27 8.1371 -1940.35 94 
3 0.004 27242.74 8.1374 -7464.88 78 
4 0.006 28483.56 8.1372 -6224.06 82 
5 0.008 29194.3 8.1375 -5513.32 84 
6 0.010 33670.99 8.1372 -1036.63 97 
7 0.016 30653.31 8.1376 -4054.31 88 
8 0.021 25814.88 8.1383 -8892.74 74 
9 0.032 31206.2 8.138 -3501.42 90 
10 0.044 29961.19 8.1381 -4746.43 86 
11 0.066 29244.2 8.1391 -5463.42 84 
12 0.089 29969.46 8.1391 -4738.16 86 
13 0.111 25664.57 8.1394 -9043.05 74 
14 0.169 26602.21 8.1403 -8105.41 77 
15 0.227 25146.69 8.1409 -9560.93 72 
16 0.287 24468.79 8.1416 -10238.83 70 
17 0.605 19456.6 8.1431 -15251.02 56 
18 0.952 17005.18 8.1457 -17702.44 49 
19 1.330 13387.22 8.1478 -21320.4 39 
 
 
